Jefferies analyst Peter Welford raised the firm’s price target on Sanofi to EUR 120 from EUR 115 and keeps a Buy rating on the shares. Q2 sales and EPS “may just meet” consensus and the 2024 outlook may be raised to flattish EPS when the company reports on July 25, the analyst tells investors in a preview note for the EU pharma group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi: Fexalimab Ph2 data showed lower key biomarker of nerve cell damage
- Sanofi investing $400M in Vigil Neuroscience, says Guggenheim
- Vigil Neuroscience announces $40M investment from Sanofi
- Regeneron/Sanofi announce NEJM publication of Dupixent Phase 3 EoE results
- Sanofi seeking initial bids for $20B consumer health unit, Bloomberg reports